Needham analyst Gil Blum maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) today and set a price target of $81.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Gil Blum’s rating is based on several positive developments for Crispr Therapeutics AG. The company has reported promising initial human trial results for its CTX310 program, which demonstrated effective dose-dependent reductions in triglycerides and LDL cholesterol, along with a favorable safety profile. This early data is encouraging and suggests potential for future success, with further updates expected in the second half of 2025 to provide additional insights.
Moreover, Crispr’s financial position remains strong, ending the first quarter of 2025 with $1.86 billion in cash, providing a solid foundation for ongoing and future projects. Additionally, the company is on track to release initial data for its CTX112 program by mid-2025, with a particular focus on safety outcomes. These factors collectively support the Buy rating, as they indicate both current progress and future potential for Crispr Therapeutics AG.
In another report released today, Chardan Capital also maintained a Buy rating on the stock with a $82.00 price target.
Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CRSP in relation to earlier this year.